Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals Incorporated, sold 11,866 shares of the company's stock on November 6, 2026. The transactions were executed at an average price of $531.53 per share, resulting in a total value of approximately $6.31 million.
This sale represents a notable transaction by a key executive within Vertex Pharmaceuticals. Insider sales can be motivated by a variety of personal financial considerations, such as diversification or tax planning, and do not necessarily indicate a change in the insider's view of the company's prospects.
Vertex Pharmaceuticals, a biotechnology company, is known for its work in developing transformative medicines for serious diseases. The company's stock performance and executive trading activity are closely watched by market participants.